重新审视危重症中的肌肉消耗:肌纤维横截面积与蛋白周转的系统评价与Meta分析
该系统评价与Meta分析纳入75项研究(2023例患者、642例对照),检索6个数据库至2025年1月。骨骼肌活检多取自股外侧肌(85%研究),主要在ICU第一周(50%研究)采集。生物学发现包括II型肌纤维萎缩伴坏死和结构变性、线粒体功能障碍、炎症/纤维化改变及泛素-蛋白酶体/自噬通路上调。6项研究(100例患者、193例对照)显示患者肌纤维横截面积较对照低22%(MD -689 µm²,95%CI -1265至-113,P=0.02;出院后MD -775 µm²,95%CI -1512至-37,P=0.04);7项研究(126例患者、61例对照)显示蛋白合成无显著差异(MD 0.007%/hr,95%CI -0.010至0.027,P=0.36);11项研究(439例患者、163例对照)显示蛋白降解通路标志物显著升高(标准化MD范围0.5-1.7)。
要点
- 危重症患者肌纤维横截面积较非ICU对照低22%(MD -689 µm²,95%CI -1265至-113,P=0.02),出院后仍低(MD -775 µm²,95%CI -1512至-37,P=0.04)。
- 蛋白合成率在危重症患者与非ICU对照间无显著差异(MD 0.007%/hr,95%CI -0.010至0.027,P=0.36)。
- 蛋白降解通路标志物在危重症患者中显著升高,标准化MD范围0.5-1.7(11项研究,439例患者、163例对照)。
- 肌肉活检主要取自股外侧肌(64项研究,85%),50%研究在ICU第一周采集,9%在ICU后采集。
- 生物学改变包括II型肌纤维萎缩伴坏死和结构变性、线粒体功能障碍、炎症/纤维化及泛素-蛋白酶体/自噬通路上调。
适用人群与场景
- 成人危重症患者,骨骼肌活检研究;对照为非ICU对照。
- 活检部位主要为股外侧肌(64项研究,85%),采集时间50%研究在ICU第一周,9%在ICU后。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 系统评价与Meta分析,纳入75项研究(2023例患者、642例对照,48个唯一患者数据集),发表于1988至2024年。
- 肌纤维横截面积:6项研究(100例患者、193例对照)显示危重症患者较对照低22%,ICU出院前MD -689 µm²(95%CI -1265至-113,P=0.02),出院后MD -775 µm²(95%CI -1512至-37,P=0.04)。
- 蛋白合成:7项研究(126例患者、61例对照)显示危重症患者与非ICU对照无显著差异(MD 0.007%/hr,95%CI -0.010至0.027,P=0.36)。
- 蛋白降解通路标志物:11项研究(439例患者、163例对照)显示危重症患者显著升高(标准化MD范围0.5-1.7)。
- 生物学发现包括II型肌纤维萎缩伴坏死和结构变性、线粒体功能障碍、炎症/纤维化改变及泛素-蛋白酶体/自噬通路上调。
证据类型、等级与局限
- 系统评价与Meta分析;检索6个数据库至2025年1月;随机效应模型分析。
- 局限性:原文未明确报告证据等级;纳入研究异质性可能影响合并结果;部分分析样本量较小(如横截面积分析仅6项研究100例患者)。
对床旁实践的改变
- 危重症肌肉消耗以蛋白降解通路上调为主,蛋白合成无显著差异,提示针对降解通路的干预可能比单纯促进合成更具潜力。
- 肌纤维横截面积在ICU期间及出院后均显著低于对照,支持对危重症患者进行肌肉保护策略的必要性。
指南或共识出处
- Crit Care Med
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To identify biological findings underlying skeletal muscle dysfunction in adults with critical illness and meta-analyze myofiber cross-sectional area and protein turnover variables.
DATA SOURCES: Six databases were electronically searched from inception to January 2025.
STUDY SELECTION: We included original studies reporting biological findings obtained from skeletal muscle biopsies of adults with critical illness.
DATA EXTRACTION: Bibliometrics, characteristics of the patients/controls, and biological findings were extracted in duplicate. Descriptive statistics of biological findings were performed. Random-effects meta-analyses investigated mean differences (MDs) in myofiber cross-sectional area and protein turnover compared with controls.
DATA SYNTHESIS: From 22,035 titles screened, 75 studies ( n = 2,023 patients; n = 642 controls) published between 1988 and 2024 were included, with 48 unique patient datasets. Biopsies were mainly collected from vastus lateralis (64 [85%] studies) during the first ICU week (50% of studies) and post-ICU (9%). Biological findings included predominant type II myofiber atrophy with necrosis and structural degeneration, mitochondrial dysfunction, inflammatory/fibrotic changes, and upregulated ubiquitin-proteasome/autophagy pathways. Data from six studies ( n = 100 patients; 193 controls) indicated that cross-sectional area was 22% lower in patients with critical illness before (MD, -689 µm 2 ; 95% CI, -1265 to -113 µm 2 ; p = 0.02) and after (MD, -775 µm 2 ; 95% CI, -1512 to -37 µm 2 ; p = 0.04) ICU discharge. Across seven studies ( n = 126 patients; 61 controls) protein synthesis was not significantly different in patients with critical illness compared with controls (MD, 0.007%/hr; 95% CI, -0.010 to 0.027; p = 0.36). Protein degradation pathway markers were significantly higher (standardized MD ranging, 0.5-1.7) in data from 11 studies ( n = 439 patients; 163 controls).
CONCLUSIONS: Muscle wasting during critical illness reflects multifaceted biological disturbances. While myofiber size is significantly lower in patients with critical illness, pooled analyses show no significant differences in muscle protein synthesis compared with non-ICU controls, whereas protein degradation markers are consistently higher.
参考来源
- González-Seguel F, Robinson CM, Caceres-Parra C, et al. Rethinking Muscle Wasting in Critical Illness: A Systematic Review and Meta-Analysis of Myofiber Size and Protein Turnover. Crit Care Med. 2026. PMID: 42565658. doi:10.1097/CCM.0000000000007288
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。